Results 11 to 20 of about 18,821 (231)

The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration

Platelets, 2022
Here, we report the in vitro characterization of the P2Y12 receptor antagonist selatogrel (ACT-246475). Binding studies with radiolabeled selatogrel demonstrated that selatogrel is a competitive antagonist of ADP binding to the P2Y12 receptor with a fast
Martine Baumann, Benoît Lack, Isabelle Guillaumat, Mark J. Murphy, Markus A. Riederer   +4 more
doaj   +2 more sources

P2Y12 receptor blockers are anti-inflammatory drugs inhibiting both circulating monocytes and macrophages including THP-1 cells [PDF]

Scientific Reports, 2021
P2Y12 blockade improves patient outcomes after myocardial infarction. As well as antithrombotic effects, anti-inflammatory effects may contribute to this beneficial clinical outcome.
Patrick M. Siegel, Laura Sander, Alba Fricke, Johannes Stamm, Xiaowei Wang, Prerna Sharma, Nicole Bassler, Ya-Lan Ying, Christoph B. Olivier, Steffen U. Eisenhardt, Christoph Bode, Ingo Ahrens, Philipp Diehl, Karlheinz Peter   +13 more
doaj   +2 more sources

Activation of dorsal horn cannabinoid CB2 receptor suppresses the expression of P2Y12 and P2Y13 receptors in neuropathic pain rats

Journal of Neuroinflammation, 2017
Background More evidence suggests that dorsal spinal cord microglia is an important site contributing to CB2 receptor-mediated analgesia. The upregulation of P2Y12 and P2Y13 purinoceptors in spinal dorsal horn microglia is involved in the development of ...
Juan Niu, Dujuan Huang, Rui Zhou, MingXia Yue, Tao Xu, Junna Yang, Li He, Hong Tian, XiaoHong Liu, Junwei Zeng   +9 more
doaj   +2 more sources

NICHE OF PRASUGREL AMONG OTHER PLATELET P2Y12-RECEPTOR INHIBITORS

Атеротромбоз, 2017
Platelet P2Y12-receptor inhibitors are ranked 2nd in terms of administration frequency among antiplatelet agents (after acetylsalicylic acid). Administration of such drugs is mandatory in conditions characterized by increased activation of platelets ...
P. S. LAGUTA, E. P. PANCHENKO
doaj   +3 more sources

Expression of ADP receptor P2Y12, thromboxane A2 receptor and C-type lectin-like receptor 2 in cord blood-derived megakaryopoiesis

Platelets, 2021
The ADP receptor P2Y12, the thromboxane A2 receptor (TXA2R) and the C-type lectin-like receptor 2 (CLEC-2) mediate platelet activation by different mechanisms. Only little is known about the expression of the receptors in human megakaryopoiesis.
Catharina Gerhards, Stefanie Uhlig, Mani Etemad, Foteini Christodoulou, Karen Bieback, Harald Klüter, Peter Bugert   +6 more
doaj   +2 more sources

Ticagrelor: Effects Beyond the P2Y12 Receptor.

Interventional cardiology clinics, 2017
Platelet P2Y12 receptor inhibitors are crucial in the treatment of patients with acute coronary syndrome or undergoing percutaneous coronary intervention.
Sumaya, W., Storey, R.F.
core   +4 more sources

Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors

Thrombosis and Haemostasis, 2014
Item does not contain fulltextDual antiplatelet therapy consisting of one of the P2Y12 receptor inhibitors in conjunction with aspirin is the mainstay of treatment for patients with acute coronary syndromes (ACS) and those undergoing percutaneous ...
Kubica, J., Navarese, E.P., Fabiszak, T., Adamski, P., Grzesk, G., Ostrowska, M., Paciorek, P., Kozinski, M.   +7 more
core   +3 more sources

The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor

Thrombosis and Haemostasis, 2010
Novel P2Y12 inhibitors are in development to overcome the occurrence of atherothrombotic events associated with poor responsiveness to the widely used P2Y12 inhibitor clopidogrel.
van Werkum, JW, Kruit, A, de Maat, Moniek; id_orcid, Rudez, Goran, Leebeek, Frank, Bouman, HJ, van den Berg, JM, Leebeek, Frank; id_orcid, Hackeng, CM, de Maat, Moniek, Ruven, HJT   +10 more
core   +3 more sources

Nanoparticle-Encapsulated Curcumin Inhibits Diabetic Neuropathic Pain Involving the P2Y12 Receptor in the Dorsal Root Ganglia

Frontiers in Neuroscience, 2018
Diabetic peripheral neuropathy results in diabetic neuropathic pain (DNP). Satellite glial cells (SGCs) enwrap the neuronal soma in the dorsal root ganglia (DRG). The purinergic 2 (P2) Y12 receptor is expressed on SGCs in the DRG. SGC activation plays an
Tianyu Jia, Tianyu Jia, Jingan Rao, Lifang Zou, Lifang Zou, Shanhong Zhao, Shanhong Zhao, Zhihua Yi, Zhihua Yi, Bing Wu, Bing Wu, Lin Li, Lin Li, Huilong Yuan, Huilong Yuan, Liran Shi, Liran Shi, Chunping Zhang, Chunping Zhang, Yun Gao, Yun Gao, Shuangmei Liu, Shuangmei Liu, Hong Xu, Hong Xu, Hui Liu, Hui Liu, Shangdong Liang, Shangdong Liang, Guilin Li, Guilin Li   +30 more
doaj   +2 more sources

The P2Y12 receptor: no active metabolite, no party

Nature Reviews Cardiology, 2009
Poor responders to clopidogrel have low levels of circulating active metabolite. However, in vitro experiments have shown that blood platelets from poor responders are fully inhibited by the active metabolite of this prodrug. Impaired platelet inhibition
Carlo Patrono, Patrono, Carlo
core   +2 more sources